Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

Table 4 In vitro immunomonitoring (Miltenyi Test): comparison between IFN-γ secreting lymphocytes after stimulation with KLH and ATL/ATH, and DTH test and clinical outcome

Patient ID	Stimulation	Baseline	After 4/6 Vaccinations	After 8/13 Vaccinations	DTH	Clinical Response
4 S.P.^a	KLH	0	0		Negative	PD
	L	0	0		Negative
9 P.M.^b	KLH		0		Negative	PR
	L		0		Negative
10 P.M.^b MR		KLH	0	0	186	Positive
	L	0	0	0	Positive
12 G.D.^b		KLH CR	133	1238	2253	Positive
	L	56	456	13405	Positive
14 T.A.^b	KLH	4	356	73	Positive	MR
	H	0	0	0	Negative
16 C.P.^b	KLH	0	103		Positive	PD
	H	0	0		Negative
18 L.B.^b	KLH	264	110		Negative	PD
	L	0	0		Negative
19 M.J.L.^b SD		KLH	0	0		Positive
	L	0	0		Positive
20 O.M.^b PD		KLH	0	0		Negative
	L	0	0		Negative
21 M.R.^b SD		KLH	0	99		Positive
	L	0	292		Positive

DTH, delayed-type hypersensitivity; L, autologous tumor lysate; H, autologous tumor homogenate; KLH, keyhole limpet hemocyanin.
^a = pts treated with iDC.
^b = pts treated with mDC.
bold = data corresponding to test

ISSN: 1479-5876